Jesús San Miguel, MD, PhD
Jesús San Miguel, MD, PhD is a professor of medicine-hematology and director of clinical and translational medicine at the University of Navarra in Spain. He served as director of the Hematology Department of the University Hospital of Salamanca in Spain, for over 22 years (1991-2013).
Dr San-Miguel has published over 700 original papers in international journals. He has made important contributions to myeloma cell biology in areas such as immunephenotyping, risk of progression from monoclonal gammopathy of undetermined significance or smouldering MM into active MM, and minimal residual disease, as well as, making important contributions in the area of therapeutics, including studies for new antimyeloma drugs at the preclinical and clinical levels, including proteasome inhibitors, immunomodulatory drugs, and histone deacetylases.
He is currently President of the International Myeloma Society and member of the Advisory Board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation. He has served as board councillor for the European Association, chairman of the Scientific Committee for the IXth Congress (2004), and president of the 15th European Hematology Association (EHA) Congress. He has been associate editor for Blood and Hematologica. He has received numerous awards, including the Waldenstöm Award, EBMT Lecture, Celgene Career Achievement Award, Kyle Lifetime Achievement Award, Jose Carreras EHA Award, Ham-Wasserman Lecture Award, Rey Jaime I Award in Clinical Medicine, and the Spanish Prizes in both oncology and translational research.
